Correction

A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Jan, 10.1007/s10875-021-01181-6, 2022)

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Volume 42, Issue 3, Pages 512-513

DOI: 10.1007/s10875-022-01219-3

Click your name to claim this paper and add it to your profile.